# Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

> **NCT05361655** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2888 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib + an aromatase inhibitor
- **DRUG:** Aromatase inhibitor

## Key facts

- **NCT ID:** NCT05361655
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 2888 (ACTUAL)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361655, "Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05361655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*